Lake Oswego, Ore.-based Biotronik, Inc. announces that it has received U.S. FDA approval of Renamic Neo, the company’s programmer for implanted cardiac rhythm management devices such as ICDs, pacemakers, and implantable cardiac monitors.
In addition to its programming functions, Renamic Neo now offers LiveSupport, which allows clinicians to share the programmer screen with, or grant programmer control to, Biotronik technical support personnel at remote locations. Renamic Neo is also compatible with Biotronik’s ReportShare and EHR DataSync to allow secure and easy integration of programmer data into hospitals’ electronic health records (EHR).
“The Renamic Neo programmer represents another advancement in providing clinicians with better tools to improve patient care,” says Sei Iwai, MD, PhD, section chief of cardiac electrophysiology at Westchester Medical Health Network in Valhalla, New York. “The LiveSupport feature, ReportShare, and EHR DataSync, plus all the connectivity options in this programmer, can improve our workflow and response time. The Renamic Neo programmer is exactly the tool we need in our device clinic.”
The Renamic Neo programmer features a 12-inch, high-contrast, LCD touchscreen display; a built-in analyzer; and battery-powered portability, as well as various connectivity options. In addition, Renamic Neo is lighter and smaller than its predecessor.
Renamic Neo will soon be available in the U.S. to hospitals and clinics that implant Biotronik cardiac rhythm management devices.
